Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Sosnowiec – page 39

1 193 clinical trials in Sosnowiec, Poland across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Sosnowiec at a glance
1 193
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 193 trials in Sosnowiec

Open in trial search

Immune system disorder

Not yet recruiting

Long-Term Safety Study of JNJ-77242113 in Children with Immune System Disorders

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Type 2 diabetes mellitus

Not yet recruiting

Phase 3 Study of Maridebart Cafraglutide versus Semaglutide as Add‑on to Metformin (± SGLT‑2 Inhibitor) in Adults with Type 2 Diabetes Not Controlled by Metformin

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Amgen Inc.

Myelodysplastic syndrome

Not yet recruiting

Study of Bexmarilimab with Azacitidine versus Placebo with Azacitidine in Treatment‑Naïve Higher‑Risk Myelodysplastic Syndrome Patients

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bexmarilimab
  • Sponsor:Faron Pharmaceuticals Oy

Safety and Efficacy of GSK5764227 with Abiraterone Acetate and Enzalutamide in Metastatic Castration‑Resistant Prostate Cancer Patients

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Glaxosmithkline Research & Development Limited

Diabetic retinal oedema

Not yet recruiting

Efficacy and Safety of Intravitreal MK-8748 Compared with Aflibercept in Adults with Diabetic Macular Edema

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Merck Sharp & Dohme LLC

Cardiac failure

Not yet recruiting

Efficacy and Safety of Fixed‑Dose Combination of Dapagliflozin, Bisoprolol Fumarate, and Eplerenone vs Usual Care in Hospitalized Acute Heart Failure Patients

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol Fumarate
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Cardiovascular disorder+2

Not yet recruiting

Phase III Study Evaluating Efficacy and Safety of Petrelintide in Participants with Overweight or Obesity and Established Cardiovascular Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Bronchitis+1

Not yet recruiting

Study of galvokimig versus placebo to assess safety and effectiveness in adults with moderate‑to‑severe chronic obstructive pulmonary disease with chronic bronchitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

Primary biliary cholangitis

Not yet recruiting

Saroglitazar hemimagnesium normalizes alkaline phosphatase in primary biliary cholangitis patients with incomplete response or intolerance to ursodeoxycholic acid

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Saroglitazar hemimagnesium
  • Sponsor:Zydus Therapeutics Inc.

Urinary retention

Not yet recruiting

Study of Teverelix in Men After First Episode of Acute Urinary Retention to Assess Prostate Size and Urinary Function

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Teverelix
  • Sponsor:Antev Limited

Phase 2 Study of Weekly Ficerafusp Alfa + Pembrolizumab vs Alternative Dosing in First‑Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ficerafusp alfa
  • Sponsor:Bicara Therapeutics Inc.

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Sosnowiec

What the registry says about research in the country

01 Respiratory Diseases

Innovative clinical trials focusing on chronic obstructive pulmonary disease (COPD) and asthma management, testing new inhaler formulations and investigating treatments for respiratory conditions including respiratory syncytial virus (RSV).

  • COPD Treatment Optimization
  • Asthma Management
  • Respiratory Infections

Studies include evaluation of triple therapy combinations and novel propellant technologies for improved drug delivery.

02 Dermatological Conditions

Research examining treatments for various skin conditions, including atopic dermatitis, psoriasis, and hidradenitis suppurativa, with particular focus on innovative biological therapies.

  • Inflammatory Skin Diseases
  • Pediatric Dermatology
  • Chronic Skin Conditions

Clinical investigations include both adult and pediatric populations, testing new targeted therapies.

03 Gastrointestinal Disorders

Studies evaluating treatments for inflammatory bowel conditions, particularly Crohn's disease and ulcerative colitis, testing novel therapeutic approaches for disease management.

  • Inflammatory Bowel Disease
  • Long-term Disease Management
  • Novel Therapeutic Approaches

Focus on both induction and maintenance therapy for moderate to severe disease states.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.